High Prevalence of Genotypic and Phenotypic HIV-1 Drug-Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'Ivoire
- 1 April 2001
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 26 (5) , 501-506
- https://doi.org/10.1097/00126334-200104150-00018
Abstract
Summary:New polymorphisms have been recently identified in CX3CRI, a corecep tor for some HIV-1 strains, one of which was associated with a strong acceleration of HIV disease progression. This effect was observed both by a case-control study in volving 63 nonprogressors (NP) from the asymptomatic long-term (ALT) cohort and Kaplan-Meier analysis of 426 French seroconverters (SEROCO cohort).These results prompted us to analyze these polymorphisms in 244 nonprogressors (NPs) and 80 rapid progressors (RPs) from the largest case-control cohort known to date, the GRIV cohort. Surprisingly, the genetic frequencies found were identical for both groups under all genetic models (p > .8). The discrepancy with the previous work stemmed only from the difference between GRIV NPs versus ALT NPs. We hypoth esized this might be due to the limited number of NPs in ALT (n = 63) and in this line we reanalyzed the data previously collected on GRIV for over 100 different genetic polymorphisms: we effectively observed that the genetic frequencies of some poly morphisms could vary by as much as 10% (absolute percentage) when computing them on the first 50 NP subjects enrolled, on the first 100, or on all the NPs tested (240 study subjects). This observation emphasizes the need for caution in case-control studies involving small numbers of subjects: p values should be low or other control groups should be used.However, the association of the CX3CR1 polymorphism with progression seems quite significant in the Kaplan-Meier analysis of the SEROCO cohort (426 individu als), and the difference observed with GRIV might be explained by a delayed effect of the polymorphism on disease. Further studies on other seroconverter cohorts are needed to confirm the reported association with disease progression. Address correspondence and reprint requests to J-F Zagury, Labo ratoire de Physiologie Cellulaire, Université Pierre et Marie Curie, 4 place Jussieu, 75005 Paris, France; e-mail:[email protected] The first two authors listed (H. Hendel and C. Winkler) made equal contributions to the work. This article does not necessarily reflect the views or policies of the U.S. Department of Health and Human Ser vices, nor does mention of trade names, commercial products, or or ganizations imply endorsement by the U.S. government. Manuscript received September 1, 2000; accepted February 23, 2001. © 2001 Lippincott Williams & Wilkins, Inc.Keywords
This publication has 13 references indexed in Scilit:
- Human Immunodeficiency Virus–Infected Persons with Mutations Conferring Resistance to Zidovudine Show Reduced Virologic Responses to Hydroxyurea and Stavudine‐LamivudineThe Journal of Infectious Diseases, 2000
- Transmission of antiretroviral-drug-resistant HIV-1 variantsThe Lancet, 1999
- HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapyAIDS, 1999
- Evaluation of HIV serial and parallel serologic testing algorithms in Abidjan, Côte d′IvoireAIDS, 1999
- Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug TherapyNew England Journal of Medicine, 1998
- Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.Journal of Antimicrobial Chemotherapy, 1998
- Antiretroviral Drug Resistance Testing in Adults With HIV InfectionJAMA, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patientsAIDS, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997